Literature DB >> 30576937

CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells.

Yi-Qiang Zhang1, Jin-Hong Pei1, Shuai-Shuai Shi2, Xiao-Su Guo3, Guo-Yan Cui4, Yun-Fei Li5, Hui-Peng Zhang6, Wen-Qing Hu7.   

Abstract

Gastric cancer is one of the most common malignant tumors worldwide and has the second highest incidence and mortality rate among malignant tumors in China. Prostate-derived Ets factor (PDEF) is a member of the Ets family of transcription factors. Although PDEF plays an important role in tumorigenesis, its biological function in gastric cancer is still unclear. Here, we evaluated PDEF expression in 30 cases of human gastric carcinoma and the corresponding peritumoral tissues, using immunohistochemistry and immunofluorescence. Significantly higher levels of PDEF were detected in tumors compared to peritumoral tissues. We then investigated PDEF expression in the gastric cancer cell lines SGC and AGS and the normal gastric epithelial cell line GES; The CRISPR/Cas9 genome-editing system was used to knockout PDEF in AGS cells as a model for gastric cancer. Cell proliferation, apoptosis, migration, and invasion of PDEF-knockout AGS cells were evaluated using CCK-8, flow cytometry, scratch wound, and transwell assays, respectively. The results illustrated that PDEF-knockout inhibited AGS cell proliferation, migration, and invasion. Taken together, the results imply that PDEF plays important roles in the proliferation, migration, and invasion of AGS cells and may serve as a new treatment target in gastric cancer.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; Cell proliferation; Gastric cancer; Invasion; Migration; PDEF

Mesh:

Substances:

Year:  2018        PMID: 30576937     DOI: 10.1016/j.biopha.2018.12.048

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 2.  CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.

Authors:  Roozbeh Moghaddar; Amirhossein Fakhre Yaseri; Sadegh Shojaei Baghini; Zhanna R Gardanova; Saeme Azizi Hassan Abadi; Burhan Abdullah Zaman; Ahmet İlhan; Navid Shomali; Ali Adili
Journal:  Cell Mol Biol Lett       Date:  2022-05-04       Impact factor: 8.702

Review 3.  Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer.

Authors:  Elvin Peter Chizenga; Heidi Abrahamse
Journal:  Pharmaceutics       Date:  2021-04-28       Impact factor: 6.321

4.  CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.

Authors:  Shuhua Zhang; Fan Zhang; Qing Chen; Chidan Wan; Jun Xiong; Jianqun Xu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-14

5.  SPDEF suppresses head and neck squamous cell carcinoma progression by transcriptionally activating NR4A1.

Authors:  Yanting Wang; Xianyue Ren; Weiyu Li; Ruoyan Cao; Suyang Liu; Laibo Jiang; Bin Cheng; Juan Xia
Journal:  Int J Oral Sci       Date:  2021-10-20       Impact factor: 6.344

Review 6.  CRISPR/Cas9 in Gastrointestinal Malignancies.

Authors:  André Jefremow; Markus F Neurath; Maximilian J Waldner
Journal:  Front Cell Dev Biol       Date:  2021-11-29

7.  Evaluation of CRISPR/Cas9 System Effects on Knocking Out NEAT1 Gene in AGS Gastric Cancer Cell Line with Therapeutic Perspective.

Authors:  Nastaran Haghighi; Abbas Doosti; Jafar Kiani
Journal:  J Gastrointest Cancer       Date:  2021-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.